At the end of January 2012, Sichuan Xieli Pharmaceutical Co., Ltd. received the EU-GMP certificate issued by the MHRA (Medicines and Healthcare Products Regulatory Agency), which not only means that Xieli Pharmaceutical's three raw material drug products, irinotecan hydrochloride, troxerutin, and rutin, have a "green pass" to the international market, but also marks Xieli Pharmaceutical's entry into the ranks of leading GMP pharmaceutical companies in the world.

　　On August 29-31, 2011, the GMP prosecutor of MHRA conducted an EU GMP on-site audit and inspection of three raw material pharmaceutical products of Xieli Pharmaceutical, confirming the GMP production management level of Xieli Pharmaceutical's products. They stated on site that they had passed the certification and would issue an EU-GMP certificate to Xieli Pharmaceutical. This certification is valid in 25 EU countries.

　　Xieli Pharmaceutical is a GMP pharmaceutical enterprise in China that produces plant-based export raw materials. Specializing in plant planting, research on extraction of natural active ingredients and synthesis of their derivatives, production of anti-tumor series and pharmaceutical preparations, it is one of the world's leading suppliers of the main flavonoid drugs rutin, troxerutin series, hesperidin, diosmin series, anti malaria drugs artemisinin, Artemether series, cytotoxic anti-tumor drugs Camptothecin, irinotecan hydrochloride.

　　At present, only a few enterprises in China have passed the GMP certification of the European Union. The EU-GMP certification is a milestone event in the development process of Xieli Pharmaceuticals, marking that Xieli Pharmaceuticals meets the requirements of EU GMP in all aspects, reaches international advanced levels, and takes a crucial step towards Xieli Pharmaceuticals' goal of becoming an internationally competitive and domestically first-class pharmaceutical manufacturing enterprise.